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 ABSTRACT 
A simple, direct and accurate spectrophotometric method has been developed for the determination of 
Glimepiride (GLM) in pure and pharmaceutical formulations by complex formation with bromocresol purple 
(BCP). The method involves the formation of a yellow ion-pair complex between BCP with glimepiride at 
pH<3,8; after reacting GLM with Na2CO3 to give C24H33N4H+O5NaS which is extracted by chloroform. The 
formed complex [GLM]: [ BCP] was measured at max 418 nm against the reagent blank prepared in the same 
manner. Variables were studied in order to optimize the reaction conditions. Molar absorptivity () for complex 
was  L.mol-1.cm-1. Beer’s law was obeyed in the concentration range of 1.226 – 46.608 g.mL-1 in present 
of 5.0x10-4 mol/l of BCP with good correlation coefficient (R2= 0.9997). The relative standard deviation did not 
exceed 3.6%. The limit of detection (LOD) and the limit of quantification (LOQ) were 0.15 and 0.46 g. mL-1, 
respectively. The proposed method was validated for specificity, linearity, precision and accuracy, repeatability, 
sensitivity (LOD and LOQ) and robustness. The developed method is applicable for the determination of GLM 
in pure and different dosage forms with average assay of 98.8 to 102.0% and the results are in good 
agreement with those obtained by the RP-HPLC reference method.   
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1. INTRODUCTION 
Glimepiride (GLM) belongs to sulfonylurea oral anti diabetic and GLM is an anti-diabetic drug which is used 
for the treatment of diabetes. GLM is a white to yellowish-white, odorless, crystalline powder insoluble in 
water. It is chemically described as 1-[[p-[2-(3-ethyl-4methyl-2-oxo-3-pyrroline-1carboxamido) ethyl] phenyl] 
sulfonyl]-3-(trans-4-methylcyclohexyl) urea (C24H34N4O5S) with a mol. mass of 490.62 g [1, 3], see Scheme 1.  
Bromocresol purple C21H16Br2O5S (BCP), acts as a weak acid in solution. It can thus be in protonated or 
deprotonated form, appearing yellow or purple, respectively, mol. mass 540.22 g [4], see scheme 2. 
Bromocresol purple has been used as a reagent to form ion pair complexes with drugs as gatifloxacin [5]. 
.  
  
 
 
 
 
 
 
The objective of present study was to develop and validate an analytical method for quantitative 
determination and dissolution studies of glimepiride in tablets. The glimepiride shows absorption maxima at 
225 nm and obeyed Beer’s law in the range of 6.0 – 14.0 μg.mL-1. The limit of detection and limit of 
quantitation were 0.06, and 0.17 μg.mL-1 respectively. Percentage recovery of glimepiride for the proposed 
method ranged from 99.32 to 100.98% indicating no interference of the tablet excipients. It was concluded 
that the proposed method is simple, easy to apply, economical and used as an alternative to the existing 
spectrophotometric and non-spectrophotometric methods for the routine analysis of glimepiride in 
pharmaceutical formulations and in vitro dissolution studies. [6]. 
Two simple and sensitive visible spectrophotometric methods have been developed for the quantitative 
estimation of glimepiride from its tablet formulation. The developed methods are based on formation of 
chloroform extractable coloured complex of drug with methylene blue and safranine. The chloroform 
extracted complex of drug with methylene blue showed absorbance maxima at 652 nm and linearity was 
observed in the concentration range of 15-50 μg.mL-1 (method-I), with safranine showed absorbance maxima 
at 536 nm and linearity was observed in the concentration range of 10-80 μg/mL (method-II). Results of 
analysis for both the developed methodswere validated statistically and by recovery studies. [7].   
            Various spectrophotometric methods [8-28] have been reported for the determination of Glimepiride 
in pure as well as in dosage forms. Most spectrophotometric methods employ extraction procedures. In this 
case, the extracted complexes were into an organic solvent, which is immiscible with water, and the 
concentration of the resulting complex in the organic phase is determined spectrophotometrically. The 
complex extraction technique has some difficulties and inaccuracies due to incomplete extraction or the 
formation of emulsions between the hydrocarbon solvent and the basic compound-containing solution. In 
response to the problems resulting from extraction of the complex, it is better to determine formed complex 
without extraction [29]. Also, none of the methods reported in the literatures is based on the formation of 
complex between BCP and GLM.  
Scheme 1: Chemical structure of Glimepiride 
 (GLM). 
 
Scheme 2: Chemical structure of Bromo cresol purple 
(BCP). 
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In this study, extraction-free spectrophotometric method for determination of GLM through ion-pair complex 
formation with BCP was developed. 
2. MATERIALS AND METHODS 
2.1. Equipment and Materials 
Spectrophotometric measurements were made in Spectro scan 80 DV UV-VIS spectrophotometr with 1 cm 
quartz cells. An ultrasonic processor model Powersonic 405 was used to sonicate the sample solutions. The 
diluter pipette model DIP-1 (Shimadzu), having 100 μl sample syringe and five continuously adjustable 
pipettes covering a volume range from 20 to 5000 μL (model Piptman P, GILSON). Centrifuge (Centurion 
Scientific Ltd., Model: K2080-Manufactured in the United Kingdom) was used for preparation of the 
experimental solutions. SARTORIUS TE64 electronic balance was used for weighing the samples. 
We used glimepiride (99.98%) was supplied by Chempi fine chemicals (INDIA), Metformin HCL (99.0%) and 
Rosuvastatin Calcium (98.6%). Bromocresol purple (99%) of analytical grade, chloroform Sigma-Aldrich and 
Na2CO3 extra pure were from MERCK. All solvents and reagents were analytical grade chemicals.  
Tablet commercial formulations were used for the analysis of GLM. The pharmaceutical formulations subjected 
to the analytical procedure were: 
(1) Amarium tablets, Racha Lab, Aleppo–Syria, each tablet contains 2 and 4 mg of GLM (Mfg. 5/2016, Exp. 
5/2018, respectively).  
(2) Amapiride tablets, Avenzor Pharmaceutical Industries, Damascus–Syria, each tablet contains 2 and 4 mg of 
GLM (Mfg. 7/2017, Exp. 7/2019, respectively). 
2.2 Standard stock solutions 
110-3 mol. L-1 of pure GLM was prepared in chloroform. This solution was prepared by good mixing 12.27 mg 
of GLM with 0.05 g of Na2CO3, adding 0.1 mL H2O, drying well in 105oC, after that it was dissolved in 
chloroform into a volumetric flask (25 mL) and diluted up to mark with chloroform. The solution was stored in 
dark bottles and kept in the refrigerator for not more than a week. The stock solution was further diluted daily 
just before the use to obtain working solutions of GLM in the concentration range 2.5-95 μM (1.226 – 46.608 
μg. mL-1 of GLM). 
Stock standard solution of Bromocresol purple (BCP) 1x10-2 mol/l: Accurately weighed 136.42 mg of BCP 
was dissolved in chloroform into a volumetric flask (25 mL) and diluted up to mark with chloroform. 
2.3 Recommended Procedure 
Aliquots of 110-3 mol. L-1 GLM solution (25, 50, 75, 100, 200, 300, 400, 500, 600, 750, 850 and 950 μL) 
containing    2.5, 5, 7.5, 10, 20, 30, 40, 50, 60, 75, 85 and 95 μM (1.226, 2.453, 3.680, 4.906, 9.812, 14.719, 
19.625, 24.531, 29.437, 36.797, 41.703, and 46.608 μg. mL-1) of GLM were transferred into a series of 10 mL 
calibrated volumetric flasks. Then 0.500 mL of BCP solution (1x10-2 mol. L-1) was added. The volume was made 
up to the mark with solvent and the absorbance was measured at max 418 nm in chloroform, against a similar 
reagent blank. 
2.4 Procedure for pharmaceutical formulations 
Twenty tablets of each studied pharmaceutical formulation were weighed accurately, finely powdered and 
mixed well. An amount of the powder equivalent to the weight of one tablet was mixed well with 0.05 g of 
Na2CO3, adding 0.1 ml H2O, drying well in 105oC, and solved in chloroform using ultrasonic for 15 min, 10 ml 
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of chloroform was added, filtered over a 10 ml flask and washed by the same solvent, then diluted to 10 ml 
with chloroform. This solution contains the following: 200 and 400 g.mL-1 of GLM for all studied 
pharmaceutical formulations contain 2 and 4 mg/tab, respectively. 
Five solutions were prepared daily by diluting 1.0 mL from each stock solution of pharmaceutical formulations 
for contents: 2 or 4 mg/tab, then 0.4 ml from stock standard solution of BCP was added and adjusted the 
volume up to 10 ml with chloroform (these solutions contain 20 or 40 g. mL-1 of GLM respectively and 4x10-4 
mol. L-1 of BCP; test solutions).  
3. RESULTS AND DISCUSSION 
3.1 The effect of solvent 
The effect of the solvents (acetone, acetonitrile, dichloroethane, dichloromethane, chloroform and 
ethylacetate) on absorbance of reagent (BCP), formed complex [GLM][BCP] and the difference between them. 
It was found that chloroform solvent was the best, see Figure 1.  
 
 
 
 
 
 
 
 
Fig. 1: Absorbance of reagent (BCP), formed complex [GLM]: [ BCP] and  
difference between them (CBCP 2.5x10-4 M, CComplex 5x10-5 M, Blank is solvent, ℓ =1 cm).  
3.2 Absorption Spectra 
UV-Vis spectra of GLM, BCP and the formed complex GLM:BCP solutions in chloroform was obtained. GLM 
solutions do not absorb in the range 300-600 nm. BCP solutions have small absorption at max 418 nm 
(≈  L mol-1 cm-1 in chloroform). [GLM]: [BCP] complex solutions have maximum absorption at max 418 nm 
in chloroform,  for the complex was  L mol-1 cm-1, see Figure 2 as example. 
3.3 Optimization of Variables 
The different experimental parameters affecting the spectrophotometric determination of GLM through ion-
pair complex [GLM]: [BCP] formation with BCP in chloroform was studied in order to determine the optimal 
conditions for the determination of GLM. 
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3.4 The effect of time and temperature 
The effect of time and temperature on the complex [GLM]: [BCP] formation was studied within the ranges 5-
120 min and 15-45oC. It was found that the formed complex wasn't affected by time or temperature at those 
ranges.  
 
 
 
 
 
 
Fig.2. UV-Vis spectra in chloroform of: 1- 0.8x10-4 mol.L-1 of GLM; 2- 5.0x10-4 mol.L-1 of BCP; 3- 0.5x10-4 
mol.L-1 ion-pair complex (0.5x10-4 mol.L-1 of GLM with 5x10-4 mol.L-1of BCP ); Blank is 5.0x10-4 mol/l of 
BCP, 4- 0.5x10-4 mol.L-1 ion-pair complex (0.5x10-4 mol.L-1of GLM with 5x10-4 mol.L-1 of BCP ); Blank is 
chloroform,  ℓ =1 cm. 
3.5 The effect of BCP concentration 
The effect of BCP concentration on complex [GLM]: [BCP] formation was investigated. It was observed that the 
absorbance of the formed complex increased coinciding with increasing the ratio of CBCP:CGLM until the ratio 
(5:1), then slowly increased until the absorbance became a quasi-static at ratio more than 10.  
3.6 Stoichiometric Relationship 
3.6.1 The molar ratio method 
The composition of GLM:BCP complex were determined by the molar ratio method and Job's method of 
continuous variation [30]. The stoichiometry of GLM: BCP complex was studied by molar ratio method 
according to following equation: Amax= f ([BCP]/[GLM]) at max 418 nm in chloroform. It confirmed that the 
binding ratio of GLM: BCP complexes are equal to (1:1); where the concentration of GLM was constant (50 M) 
and the concentrations of BCP changed from 0 to 250 M, see Figure 3. The formation constant of the ion pair 
complex [GLM]: [ BCP] is 2.81x108 in chloroform. 
 
  
 
 
 
 
Fig.3. Molar ratio method to calculate binding ratio of GLM:BCP complex at max 418 nm in chloroform 
([GLM]= 50 M, blank is chloroform, ℓ =1 cm). 
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3.6.2 The Job's method 
Continuous variation was utilized to check the composition of GLM:BCP complex at max 418 nm in chloroform. 
The absorbance of the complex in used solvent were plotted against the mole fraction [BCP]/([GLM]+ [ BCP]), 
where [GLM]+ [ BCP] =100 M. The plot reached maximum value at a mole fraction of 0.5, see Figure 4. This 
indicated complex formation (GLM: BCP) in the ratio of (1:1). The formation constant of the ion- pair complex 
[GLM]: [BCP] is 2.44x108. 
 
 
 
  
 
 
 
Fig.4. Job's method of continuous variation to calculate binding ratio of GLM: BCP complex at max 418 nm                                                                
in chloroform ([GLM]+ [ BCP] =100M, blank is chloroform, ℓ =1 cm). 
3.7 Mechanism of reaction 
Anionic dyes such as BCP form ion-pair complexes with the positively charged nitrogen-containing molecule. 
The colour of such dyes is due to the opening of lactoid ring and subsequent formation of quinoid group 
(deprotonated). Glimepiride (C24H34N4O5S) is reacted with Na2CO3 to give (C24H33N4H+O5NaS), then dissolved 
in chloroform and forms yellow ion-pair complex with the dye at pH<3.8; (in pH>5.4 and alkaline solution BCP 
gives blue colour). Each drug-dye complex with two oppositely charged ions (positive on the drug and 
negative on the dye) behaves as a single unit held together by an electrostatic binding [14, 24-27]. The 
suggested mechanism of GLM- BCP ion-pair complex formation is shown in Scheme 3. 
 
 
 
 
 
 
 
 
 
Scheme 3: The possible reaction mechanism of [GLM]: [BCP] complex formation. 
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3.8 Calibration curve 
The calibration curve of GLM in pure form through complexation with BCP showed excellent linearity over 
concentration range of 1.226 – 46.608 μg. mL-1 in presence of 5.010-4 mol. L-1 of BCP with good correlation 
coefficient (R2= 0.9997) in chloroform. Regression equation at max was as the follows: y=0.0421x+0.0023 in 
chloroform. Figures 5 and 6 showed the spectra of [GLM]: [ BCP] complex in presence of 5.0×10-4 M of BCP as 
example. The spectra characteristics of the method such as the molar absorptivity (), Beer's law, regression 
equation at max (y=a.x+b); where y=absorbance, a=slope, x=concentration of GLM by μg. mL
-1, b=intercept, 
the correlation coefficient, limit of detection (LOD) and limit of quantification (LOQ) and the optimum 
conditions for spectrophotometric determination of GLM through ion-pair complex formation using BCP in 
chloroform is summarized in Table 1. 
 
 
 
 
        
  
 
          
Fig.5. Spectra of [GLM]: [BCP] complex in presence of 5.010-4 M of BCP; where CGLM as the follows: 1.226, 
2.453, 3.680, 4.906, 9.812, 14.719, 19.625, 24.531, 29.437, 36.797, 41.703 and 46.608 μg. mL-1 {Blank is BCP 
solution in chloroform 5.010-4 M; ℓ = 1cm}.  
 
 
 
 
 
 
 
 
Fig. 6: Calibration curve for determination of GLM according to optimal conditions at λmax 418 nm (in present 
of 5.010-4 M of BCP) where GLM: 1.226 – 46.608 μg.mL-1 {Blank is BCP solution in chloroform 5.010-4 M; ℓ = 1 
cm}. 
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Table 1. The parameters established for spectrophotometric determination of GLM by complex formation with 
BCP in chloroform. 
Parameters Operating values 
max of GLM: CPB complex, nm 418 
Beer’s Law Limit, for CGLM by μM  2.5-95 
Beer’s Law Limit, for CGLM by μg. mL-1  1.226 – 46.608 
Molar absorptivity of [GLM]: [BCP] complex ()L.mol-1.cm-1  20600
 
Regression equation for [GLM]: [BCP] at max =418 nm:  
Slope 0.0421 
Intercept 0.0023 
Correlation coefficient (R2) 0.9997 
LOD for CGLM by μg. mL-1  0.15 
LOQ for CGLM by μg. mL-1  0.46 
RSD%  3.6 
CBCP: CGLM, M ≥5 
Stability  24 h 
Temperature of solution 20±5oC 
    n=5, t=2.776. 
4. Analytical results 
Spectrophotometric determination of GLM through complexation with BCP in chloroform within optimal 
conditions using calibration curve was applied. The results, summarized in Table 2, showed that the 
determined concentration of GLM was rectilinear over the range of 1.226 – 46.608 μg. mL-1, with relative 
standard deviation (RSD) not more than 3.6%. The results obtained from the developed method have been 
compared with the official RP-HPLC method [30] and good agreement was observed between them. 
Table 2: Spectrophotometric determination of GLM through complex formation with BCP within optimal 
conditions using calibration curve in chloroform. 
 
 
 
 
 
 
 
 
 
 
   
                
                                    * n=5, t= 2.776.        
 1-g. mL*X ,  
RP-HPLC [31]   
RSD% n
SDt
x
.
  
g. mL-1 
*x ±SD, 
g. mL-1 
(Found) 
Xi, 
g. mL-1 (Taken) 
1.216 3.6 1.235± 0.0552 1.235±0.0445 1.226 
2.436 3.4 2.553± 0.108 2.553±0.087 2.453 
3.721 3.2 3.824± 0.152 3.824±0.122 3.680 
4.926 3.0 5.064± 0.189 5.064±0.152 4.906 
9.925 3.0 9.812± 0.365 9.812±0.294 9.812 
14.897 3.0 14.316± 0.533 14.316±0.429 14.719 
18.782 2.8 19.637± 0.683 19.637±0.550 19.625 
25.214 2.6 24.133± 0.779  24.133±0.627 24.531 
29.890 2.5 29.732± 0.923 29.732±0.743 29.437 
38.125 2.4 36.805± 1.097 36.805±0.883 36.797 
42.250 2.3 41.722± 1.191 41.722±0.960 41.703 
46.889 2.2 46.456±1.2688 46.456±1.022 46.608 
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5. Applications 
The developed spectrophotometric method was applied to determine GLM in some pharmaceutical 
preparations through complex formation by BCP in chloroform according to the optimal conditions. The 
results of quantitative analysis for GLM in pharmaceutical preparations were summarized in Table 3. The 
proposed method was simple, direct, specific and successfully applied to the determination of GLM in 
pharmaceuticals without any interference from excipients. Average recovery ranged between 98.8 to 102.0%. 
The results obtained by this method agree well with the contents stated on the labels and were validated by 
RP-HPLC method [31]. 
Table 3: Determination of GLM, in some Syrian pharmaceutical preparations using spectrophotometric method 
through complex formation with BCP in chloroform, max 418 nm.  
Tablet dosage 
form 
Label Claim  
of GLM, 
mg/tab. 
*Mean ±SD  
(GLM),  
mg/tab. 
 
RSD% Assay % 
*Mean ±SD 
(GLM),  
mg/tab.  
by RP-HPLC 
[31] 
* Assay %, 
by RP-HPLC 
[31] 
Amarium 
2 1.990±0.062 3.1 99.5 2.016±0.042 100.8 
4 3.972±0.111 2.8 99.3 3.996±0.056 99.9 
Amapiride 
2 2.040±0.061 3.0 102.0 2.030±0.038 101.5 
4 3.952±0.115 2.9 98.8 3.960±0.055 99.0 
* n=5.  
6. METHOD VALIDATION 
The developed method for simultaneous estimation of GLM has been validated in accordance with the 
International Conference on Harmonization guidelines (ICH) [32]. 
6.1 Selectivity and Specificity 
Selectivity test determines the effect of excipients on the assay result. To determine the selectivity of the 
method, standard solution of GLM, commercial product solution and blank solutions were analyzed. The 
results of the tests proved that the components other than the drug did not produce any interfere. The 
specificity of the method was ascertained by analyzing standard GLM in presence of excipients. There was no 
interference from most of the common excipients. 
6.2 Linearity 
Several aliquots of standard stock solution of GLM were taken in different 10 ml volumetric flask and diluted 
up to the mark with chloroform such that their final concentrations were 1.226 – 46.608 μg. mL-1 for GLM. 
Absorbance was plotted against the corresponding concentrations to obtain the calibration graph, see Figure 
5 and Table 3. Linearity equations obtained were y=0.042x+0.0023 for the range 1.226 – 46.608 μg. mL-1 
(R2=0.9997).  
6.3 Precision and Accuracy 
The precision and accuracy of proposed method was checked by recovery study by addition of standard drug 
solution to pre-analyzed sample solution at three different concentration levels (80%, 100% and 120%) within 
the range of linearity for GLM. The basic concentration level of sample solution selected for spiking of the 
GLM standard solution was 14.719 μg. mL-1. The proposed method was validated statistically and through 
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recovery studies and was successfully applied for the determination of GLM in pure and dosage forms with 
percent recoveries ranged from 99.8% to 102.2%, see Table 4.  
Table 4: Results of recovery studies (n=5). 
Level % Recovery 
80% 100.1 
100% 99.8 
120% 102.2 
 
7.4 Repeatability and Robustness 
The repeatability was evaluated by performing 10 repeat measurements for 14.719 μg. mL-1 of GLM using the 
studied spectrophotometric method under the optimum conditions. The found amount of GLM (x ± SD) 
14.338 ± 0.420 μg. mL-1 and the percentage recovery was found to be 99.7 ± 2.85. These values indicate that 
the proposed method has high repeatability for GLM analysis. The robustness of the method adopted is 
demonstrated by the constancy of the absorbance with the deliberated minor change in the experimental 
parameters such as the change in the concentration of excipients, CBCP: CGLM (10±5%), temperature (20±5oC), 
stability (24±0.5 h) and reaction time (5±1 min), see Table 5 which indicates the robustness of the proposed 
method. The absorbance was measured and assay was calculated for five times. 
Table 5: Robustness of the proposed spectrophotometric method. 
Experimental parameter 
variation 
 
Average recovery (%)*  
CGLM 
4.906 g.mL-1 36.797 g.mL-1 
Temperature 
15oC 
25oC 
 
99.6 
100.7 
 
99.9 
100.9 
Stability 
23.5 h 
24.5 h 
 
102.4 
102.6 
 
100.0 
100.5 
Reaction time 
4.0 min 
6.0 min 
 
99.8 
102.7 
 
99.7 
101.2 
                           * n=5. 
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6.5 Sensitivity (LOD and LOQ) 
The sensitivity of the method was evaluated by determining the LOD and LOQ. The values of LOD and LOQ for 
GLM are 0.15 and 0.46 μg. mL-1, respectively. 
6.6 The homogenization of tablets  
The homogenization of tablets in terms of the weight and the amount of drug was studied. We found that the 
mean weight and amount drug in the tablets was 0.1793 ± 0.0030 g (i.e. ±1.67%), 0.1794 ± 0.0023 g (i.e. 
±1.17%) for Amarium tablets (2 and 4 mg/tab) and 0.1005 ± 0.0015g (i.e. ±1.49%) and 0.0993 ± 0.0012 g (i.e. 
±1.21%) Amapiride tablets (2 and 4 mg/tab), respectively. While the mean amount drug in the tablets was 
1.999±0.070 mg/tab (i.e. ±3.5%) and 3.965±0.119 mg/tab (i.e. ±3.0%) for Amarium tablets (2 and 4 mg/tab) 
and 2.036±0.069 mg/tab (i.e. ±3.4%) and 3.945±0.122 mg/tab (i.e. ±3.1%) for Amapiride tablets (2 and 4 
mg/tab), respectively; which shows that homogeneity of tablets is good. 
6.7 Interferences  
Metformin HCL up to 1000 mg with 2 mg of glimepiride does not interfere, but Pioglitazone HCL and 
Rosuvastatin Calcium interfere. 
7. CONCLUSION 
The developed spectrophotometric method is simple, direct (extraction-free) and cost-effective for the 
determination of GLM in pure and tablet dosage forms. This method is based on formation of ion-pair 
complex between GLM and BCP in chloroform ([GLM]: [BCP]). Beer’s law in the optimum experimental 
conditions using [GLM]: [BCP] complex is valid within a concentration range of 1.226 – 46.608 μg/ml. The 
developed method is applied for the determination of GLM in pure and its commercial tablets without any 
interference from excipients with average assay of 98.8 to 102.0%. 
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